Both Ofev (nintedanib) and Esbriet (pirfenidone) were approved by the FDA on October 15, 2014 for the treatment of idiopathic pulmonary fibrosis (IPF). This is big for anyone suffering from this condition—these are the first two medications to be proven to slow the progression of IPF, which is usually a fatal disease.
First, what is idiopathic pulmoary fibrosis?
Idiopathic pulmonary fibrosis (IPF) is a condition where the tissue in the lungs thickens and turns into scar tissue over time. See More